Panitumumab Beats Bevacizumab in Left-Sided mCRC

The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.

Related Keywords

Japan ,United States ,Japanese ,American ,Takayuki Yoshino ,Cathy Eng ,National Cancer Center Hospital ,American Society Of Clinical Oncology ,Drug Administration ,American Society ,Clinical Oncology ,National Cancer Center Hospital East ,Colorectal Cancer ,Chemotherapy ,Antiangiogenesis ,Angiogenesis Inhibitor ,Evacizumab ,Nhibitor Angiogenesis ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Neoplasm ,Tumor ,Metastasis ,Clinical Research ,Clinical Trials ,Linical Studies ,Epidermal Growth Factor Receptor ,Egfr ,Genomics ,Genomic Medicine ,Edicine Genomic ,Humanized Monoclonal Antibody ,Rastuzumab ,Primary N ,